The opening post describes the usual case. This is about the unusual one. Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet…
Cross-border purchase within the EU: the actual rules Writing it up because I had to work it out twice and would rather nobody else did.
Two things I would like separated before anyone answers on cross-border purchase within, because they get bundled and then argued about as one thing.
The first is descriptive: what has actually been observed, by whom, and how. The second is causal: why. I am asking about the first only.
The opening post describes the usual case. This is about the unusual one.
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).
Worth one more sentence than it usually gets.
Adding the measurement that the opening post says would settle it.
Import rules for personal quantities are jurisdiction-specific and change without much publicity. Establishing your own position is unavoidable.
Small point, but it is the one that usually catches people.
I would be cautious about generalising from the cross-border purchase within example above. It is a good example. It is one example.
Practical experience of cross-border purchase within, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.
On post #5 — agreed on the reasoning, with one qualification.
Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.
If that reads as pedantic, it is, and it has saved me twice.
Fair, and the limits you put on it are the part I will remember.
Post #5 put the caveat in the right place and I want to underline it.
Customs practice varies between entry points within the same country, which is why two people in the same jurisdiction report different experiences honestly.
Reading rather than contributing, but this is the most useful thread I have found on it.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Travelling with an injectable: documentation and practicalities
Posting this under the heading it deserves: Travelling with an injectable: documentation and practicalities Everything below is what sits behind that. Documenting a stated criterion rather than an outcome,…
|
+37 | 42 | 2.1k | 1d |
|
Availability by country, dated, with primary sources — one year on
Availability by country, dated, with primary sources — one year on — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this…
|
+7 | 11 | 850 | 7mo |
|
What changed in 2026, by region — does this still hold?
What changed in 2026, by region — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated, because everything in…
|
+20 | 25 | 50k | 1d |
|
Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
|
+72 | 81 | 6.9k | 8mo |
|
Personal import allowances, compared — a second dataset
Personal import allowances, compared — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Personal import allowances. It is mine, it is…
|
+124 | 132 | 9.2k | 2mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] What a good consultation looks like from the other side
The question in the title: What a good consultation looks like from the other side I will give what I have already checked below so nobody repeats it. Good consultation: what I expected, what I found, and the…
|
+32 | 36 | 13k | 1mo |
|
What to bring: records that a clinician can actually use — a second dataset
What to bring: records that a clinician can actually use — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. A question about how to describe something…
|
+80 | 86 | 5.6k | 3h |
|
Discussing something you have already been doing
On the subject in the title: Discussing something you have already been doing Working notes rather than a conclusion. A question about how to describe something to a clinician rather than about the thing…
|
+10 | 14 | 3.4k | 10mo |
|
Why a compound being unapproved is not the same as being illegal to possess
Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Collecting what is known about compound…
|
+72 | 78 | 23k | 3mo |
|
Irish differences from the UK position
Posting this under the heading it deserves: Irish differences from the UK position Everything below is what sits behind that. Trying to establish the boundary conditions on irish differences. The general…
|
+62 | 66 | 993 | 21mo |